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node metastasis in young TNBC patients. Our results showed
that NOS3 expression level was reciprocally up-regulated.On
the molecular level, sONE siRNAs resulted in an increase in
NOS3 levels and NO production in MDA-MB-231. On the
functional level, knocking down of sONE levels resulted in a
significant increase of cellular viability and cellular prolifera-
tion rates of MDA-MB-231
Conclusion This study highlights a novel prognostic value of
sONE in young TNBC patients where sONE expression level
was negatively correlated with the aggressiveness of the dis-
ease. Moreover, this study validated sONE/NOS3/NO as a
novel tumour suppressor signalling axis in BC patients.
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Introduction Chromosome 8q24 prostate cancer (PCa) suscept-
ibility region encodes miR-1207–3 p which directly targets
fibronectin type III domain containing 1 (FNDC1) to regulate
fibronectin (FN1) and subsequently the androgen receptor
(AR), and FNDC1/FN1/AR is overexpressed in metastatic PCa
(Das et al, Exp Cell Res, 2016).
Material and methods Expression of miR-1207–3 p and c-MYC
in histologically confirmed normal prostate, benign prostatic
hyperplasia (BPH) and PCa from prostatectomy or transrectal
ultrasound-guided biopsies was analysed. Molecular mecha-
nisms were elucidated using mCRPC cell lines. Effects of
NB1207 and NB5, two novel synthetic analogues of miR-
1207–3 p, on AR-V7 (implicated in PCa therapeutic resist-
ance), mCRPC tumour growth in mice were studied.
Results and discussions miR-1207–3 p is underexpressed in
PCa (0.10±0.02, 95% CI [0.1, 0.2], p=0.000) in comparison
to normal prostate (1.02±0.17, 95% CI [0.7, 1.4], p=0.000)
and BPH (0.74±0.15, 95% CI [0.4, 1.1] p=0.004). c-MYC
was overexpressed in PCa (34.76±8.11, 95% CI [18.1, 51.4],
p=0.000; normal: 1.99±0.34, 95% CI [1.3, 2.7]; BPH: 1.01
±0.21, 95% CI [0.6, 1.4], p=0.000). miR-1207–3 p was
underexpressed by nearly 3-fold in PCa with Gleason
score 8 versus those with Gleason score <8, while c-MYC
was overexpressed by nearly 5-fold in PCa with Gleason
score 8 versus those with Gleason score <8. NB1207 signifi-
cantly inhibited c-MYC expression in mCRPC cell lines: PC-3,
E006AA-hT and C4-2B. miR-1207–3 p regulates c-MYC
expression via the miR-1207–3 p/FNDC1/FN1/AR pathway: c-
MYC protein expression is inhibited in mCRPC cell lines by
overexpression of miR-1207–3 p, and by inhibition of expres-
sion of FNDC1, FN1, and AR. In AR-V7-expressing mCRPC
cell lines, NB1207 and NB5 significantly reduced AR-V7
expression, and NB1207 and NB5 more effectively inhibited
AR-V7 compared to abiraterone, enzalutamide and apaluta-
mide. In mCRPC cell lines, abiraterone, enzalutamide, and
apalutamide failed to significantly inhibit cell proliferation or
induce apoptosis. However, NB1207 and NB5 significantly
inhibited proliferation and induced apoptosis. In mCRPC
22RV1 tumor-bearing mice, NB5 and NB1207 significantly
inhibited tumour growth and metastatic spread. While enzalu-
tamide minimally inhibited growth of 22RV1 tumours in
mice, apalutamide and abiraterone had no inhibitory effects
on tumour growth.
Conclusion This study shows potential diagnostic and prognos-
tic value of miR-1207–3 p in mCRPC, and that NB5 and
NB1207, novel analogues of miR-1207–3 p, may be candidate
therapeutics for mCRPC.
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Introduction Of the total human DNA only 1.2% o codes for
proteins, with the rest only being transcribed into regulatory
RNA, known as non-coding RNA. Long non-coding RNAs
(lncRNAs) are non-coding RNAs that have no or limited pro-
tein-coding potential, are >200 nt in length and include-
among other categories- long/large intergenic/intervening RNAs
(lincRNAs), intronic lncRNAs, natural antisense transcripts
(NATs) and pseudogenes. lncRNAs are key regulators of sev-
eral cellular processes and have been associated with a variety
of diseases, including cancer. Metformin (N, N-dimethyl bigua-
nide) is an oral biguanide already in clinical use against diabe-
tes and has also been suggested to decrease the incidence of
various cancers, including neuroblastoma, the most common
extracranial paediatric cancer arising at the sympathetic nerv-
ous system.
Material and methods The present study aimed at assessing the
differential expression of protein-coding and, primarily, non-
protein-coding RNAs between control untreated SH-SY5Y neu-
roblastoma cells and cells resistant to 3 mM Metformin via a
paired-end RNA sequencing approach.
Results and discussions In the first data set (untreated cells
compared to cells resistant to 3 mM Metformin), out of
13 741 genes measured, 7855 genes were found to be differ-
entially expressed with 108 of them falling within the lncRNA
category. Among these 33 comprise lincRNAs, 24 are NATs
and 18 pseudogenes. In the second data set (untreated cells
compared to cells treated with 20 mM Metformin) 13 481
genes were tested, of which 5652 showed perturbed expres-
sion. Among them, 86 belong to the lncRNA category, and in
particular, 33 are lincRNAs, 19 are NATs and 13 are pseudo-
genes. Interestingly, 34 of the assessed lncRNAs display differ-
ential expression in both data sets. The results were obtained
using a threshold of 0.05 for statistical significance (p-value)
and a log fold change of expression with an absolute value of
at least 0.6.Neuroblastoma cells’ response to Metformin, as
well as the acquisition of resistance to the drug, trigger the
differential expression of a great diversity of lncRNAs.
Conclusion Given that Metformin is an appealing and promis-
ing therapeutic approach against neuroblastoma, these
lncRNAs could, in turn, be used as molecular biomarkers
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towards better prediction, prognosis and diagnosis of the dis-
ease. Moreover, such an approach would be of interest as
part of a combination therapy.
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Introduction MicroRNAs (miRNAs) are involved in the regula-
tion of gene expression in colorectal cancer (CRC), which has
specific biological pathways that are predominant in either
left- or right-sided CRC. However, it is unclear how miRNAs
are associated with biological pathways in these two forms of
CRC. Our hypothesis is that a comprehensive understanding
of the fundamental biological signalling pathways in the two
sides of CRC may aid in developing a decisive step towards
precision medicine. We aim to clarify specific biological path-
way differences of differentially expressed miRNAs between
left- and right-sided CRC.
Material and methods We extracted total RNA from 24 of
left- and right-sided CRC tumour samples from Finnish
patients using the mirVanaTM miRNA Isolation Kit (Thermo
Fisher Scientific) in the discovery cohort. Libraries for small
RNA sequencing were prepared using TruSeq
®
Small RNA
Library Prep Kit (Illumina) and run on Illumina MiSeq. Differ-
entially up-regulated miRNAs were identified using DeSeq2.
For validation purposes, we used the mature miRSeq dataset
of 201 CRC samples from The Cancer Genome Atlas. We
analysed biological pathways of site-specific miRNAs from the
discovery and validation cohorts using the DIANA/mirPath
tool.
Results and discussions We found 17 and 15 differentially up-
regulated miRNAs in left- and right-sided CRC, respectively,
in the discovery cohort. The left miRNAs were involved in
the mTor, Wnt, PI3K-Akt signalling pathways. These pathways
are the predominant pathways in left-sided CRC. The Wnt
signalling pathway was also significant (false discovery
rate <0.05) in the left miRNAs from the validation cohort. In
the discovery cohort, the right miRNAs were involved in the
TGF-b signalling pathway. This pathway is dominant in right-
sided CRC also in earlier reports. Alongside with the pathway
findings, we found that the discovery and validation cohorts
share six miRNAs. One of these (hsa-miR-196b-5p) was differ-
entially up-regulated in left-sided CRC and the rest of them
(hsa-miR-625–3 p, hsa-miR-155–5 p, hsa-miR-625–5 p, hsa-
miR-31–5 p and hsa-miR-330–5 p) in right-sided CRC.
Conclusion Our findings highlight that there are site-specific
miRNAs in left and right-sided CRC. The results also indicate
the involvement of these left and right miRNAs in different
predominant biological pathways of the two forms of CRC.
This exploration may be useful for further studies on the
development of diagnosis in left- and right-sided CRC.
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Introduction Long non-coding RNAs (lncRNAs) are kind of
non-coding RNAs (ncRNAs). The length of lncRNAs is more
than 200 nucleotides. A few decades ago, lncRNAs were
regarded as useless parts of the genome, but more and more
studies demonstrate that lncRNAs play an important role in
growth, development, metabolism and cancer. Very few
lncRNAs have been characterised in detail at the present time.
However, it is clear that lncRNAs are important regulators of
gene expression and have a wide range of functions in cellular
and developmental processes. Previous studies have shown that
development of cancers is accompanied by abnormal expres-
sion of lncRNAs that participate in the regulation of cancer
metastasis, apoptosis and proliferation. Melatonin is a hor-
mone secreted from pineal gland and play an important role
in the regulation of the immune system. Melatonin is also a
potent antioxidant agent. Previous studies have shown that
melatonin inhibits the growth and metastasis of breast cancer
cells, cervical cancer cells and ovarian cancer cells. However,
the detailed effects and mechanisms of melatonin and
lncRNAs on oral cancer cell metastasis were still unclear.
Material and methods RNA-seq and quantitative real-time PCR
analyses were used to detect the lncRNAs and mRNAs expres-
sion in HSC-3, HSC-4 and OECM-1 oral cancer cells. Trans-
well migration assay was performed to evaluate the migration
of tumour cells. Fluorescent in situ hybridization (FISH) assay
was used for determining the lncRNAs levels in oral cancer
cell. Protein levels were accessed by western blotting assay.
Results and discussions The results show that melatonin could
induce the PRUNE2 through decreasing lncRNA-LNC310 to
improve the migration inhibition of oral cancer cells. On the
other hand, melatonin could partially inactivate Src/STAT3 sig-
nalling cascade targeting LNC310 to induce the expression of
PRUNE2 in oral cancer cells. Additionally, LNC310 knock-
down upregulated PRUNE2 expression and suppressed cell
migration in oral cancer cells.
Conclusion This results suggested that melatonin inhibited oral
cancer migration by inducing lncRNA-LNC310-mediated
PRUNE2 expression and indicated that melatonin could be a
promising treatment for oral cancer.
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Introduction Lapatinib is a dual receptor tyrosine kinase inhib-
itor that blocks EGFR (HER1) and HER2 activation in breast
cancer. microRNAs (miRNA) are non-coding RNAs involved
in the regulation of protein-coding genes and these regulatory
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